Market research
4OR1.F Organovo Holdings, Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 49M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.66
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US68620A2033
- Market cap
- 49M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.66
About
About Organovo Holdings, Inc
Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat end-stage liver, life-threatening, and orphan diseases. The company was incorporated in 2007 and is headquartered in Solana Beach, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 4OR1.F discussion.
5 years, 5 months ago
Organovo Holdings, Inc is currently in a long term downtrend where the price is trading 23.7% below its 200 day moving average.
From a valuation standpoint, the stock is 78.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 279.1.
Organovo Holdings, Inc's total revenue sank by 100.0% to $0 since the same quarter in the previous year.
Its net income has increased by 25.5% to $-3M since the same quarter in the previous year.
Finally, its free cash flow fell by 206.2% to $-2M since the same quarter in the previous year.
Based on the above factors, Organovo Holdings, Inc gets an overall score of 2/5.